共 93 条
[1]
Lilleness B(2019)Development and validation of a survival staging system incorporating BNP in patients with light chain amyloidosis Blood 133 215-223
[2]
Ruberg FL(2018)A new staging system for cardiac transthyretin amyloidosis Eur Heart J 39 2799-2806
[3]
Mussinelli R(2020)Diuretic dose and NYHA functional class are independent predictors of mortality in patients with transthyretin cardiac amyloidosis JACC CardioOncol 2 414-424
[4]
Doros G(2014)Left ventricular amyloid deposition in patients with heart failure and preserved ejection fraction JACC Heart Fail 2 113-122
[5]
Sanchorawala V(2020)Atrial fibrillation in transthyretin cardiac amyloidosis: predictors, prevalence, and efficacy of rhythm control strategies JACC Clin Electrophysiol 6 1118-1127
[6]
Gillmore JD(2016)Occult transthyretin cardiac amyloid in severe calcific aortic stenosis: prevalence and prognosis in patients undergoing surgical aortic valve replacement Circ Cardiovasc Imaging 9 e005066-58
[7]
Damy T(2021)Daratumumab-based treatment for immunoglobulin light-chain amyloidosis N Engl J Med 385 46-123
[8]
Fontana M(2021)Efficacy of tafamidis in patients with hereditary and wild-type transthyretin amyloid cardiomyopathy: further analyses from ATTR-ACT JACC Heart Fail 9 115-21
[9]
Cheng RK(2018)Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis N Engl J Med 379 11-31
[10]
Levy WC(2018)Inotersen treatment for patients with hereditary transthyretin amyloidosis N Engl J Med 379 22-981